Clinical AI founders face a dangerous balance: regulatory paralysis blocks progress, while unconstrained experimentation risks patient harm.
Clinical AI founders face a dangerous balance: regulatory paralysis blocks progress, while unconstrained experimentation risks patient harm.
More from this video
See all →In a Utah pilot, 97–98% of prescription refills were judged concordant with human physician…
Doctronic completed nearly 30 million AI consultations while direct-to-consumer revenue…
The system currently measures around 50 biomarkers, with ambitions to increase that number by…
More than $1.2 trillion of roughly $5 trillion in healthcare spending is administrative.
Doctronic combines autonomous symptom intake and triage with telehealth, creating a path from…
Consumer loyalty to a recurring health experience can turn repeated visits into the foundation for…
A multimodel, multi-agent architecture routes each patient-journey stage to its most effective…
Clinical guidelines for LLMs should follow a patient’s journey through a specific condition over…
Don't lose this one
A free account saves insights like this to your Boards, and Korva resurfaces them so you actually remember.